Evolus Inc EOLS
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-02-08 |
| Shares Out. | 65,850,000 |
| Website | evolus.com/ ↗ |
| Phone | 18887057274 |
| Employees | 350 |
| Revenue | $73.1M |
| Gross Profit | $48.9M |
| Net Income | -$10.7M |
| Free Cash Flow | -$43.6M |
| Total Assets | $220.6M |
| Total Liabilities | $249.4M |
| Equity | -$28.8M |
About Evolus Inc
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Evolus Inc is a publicly traded company under the ticker symbol EOLS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)